

DIAGNOSTIC VALUE OF JAK2 V617F MUTATIONAL SCREENING IN PATIENTS WITH BUDD-CHIARI SYNDROME

Thesis

Submitted for Partial Fulfillment of MD Degree
In Clinical Pathology

By

Esraa Mansour Shehata Hassan
(M.B., B.Ch. and M.Sc)
Clinical Pathology

Supervised by

Prof. Dr. Iman Mohamed Amin Omar

Professor of Clinical Pathology
Faculty of Medicine - Ain Shams University

Dr. Mona Fathey Abd Elfattah

Assistant Professor of Clinical Pathology
Faculty of Medicine - Ain shams University

Dr. Noha Bassiouny Hassan Mostafa

Lecturer of Clinical Pathology
Faculty of Medicine - Ain shams University

Faculty of Medicine
Ain Shams University

List of Contents

Title	Page
▪ List of Abbreviations.....	i
▪ List of Tables.....	iii
▪ List of Figures.....	v
▪ Introduction.....	1
▪ Aim of the Study.....	3
▪ Review of Literature	
- Chapter (1): Budd Chiari Syndrome	4
- Chapter (2): Janus Kinases	33
▪ Subjects and Methods.....	46
▪ Results	58
▪ Discussion	71
▪ Summary and Conclusion.....	78
▪ Recommendations	81
▪ References.....	82
▪ Arabic Summary.....	--

List of Abbreviations

ALT	Alanine Aminotransferase
APTT	Activated Partial Thromboplastin Time
ARMS	Amplification Refractory Mutation System
AST	Aspartate Aminotransferase
BCS	Budd-Chiari Syndrome
C	Carboxy Domain
CALR	Calreticulin
COS	Cut-Off Sample
CT	Computed Tomography
ET	Essential Thrombocythemia
FERM	Band 4.1, Ezrin, Radixin and Moesin
FVL	Factor V Leiden
GZ	Gray Zone
Hb	Hemoglobin
HCC	Hepatocellular Carcinoma
HS	Highly Significant
HVOTO	Hepatic C Venous Outflow Tract Obstruction
IL	Interleukin
INR	International Normalized Ratio
IVC	Inferior Vena Cava
JAK	Janus Kinases
JAK2	Janus Kinase 2
JH1	JAK Homology 1
JH2	JAK Homology 2
LHV	Left Hepatic Vein

List of Abbreviations

MHV		Main Hepatic Vein
MPL		Myeloproliferative Leukemia
MPNs		Myeloproliferative Neoplasms
MRI		Magnetic Resonance Imaging
MTHFR		Methylenetetrahydrofolate Reductase
NC		Negative Control
NRatio		Normalized Ratio
NS		Non-Significant
OLT		Orthotopic Liver Transplantation
PB		Peripheral Blood
PC		Positive Control
PCR		Polymerase Chain Reaction
Ph		Philadelphia
PMF		Primary Myelofibrosis
PNH		Paroxysmal Nocturnal Hemoglobinuria
PT		Prothrombin Time
PV		Polycythemia Vera
PV		Portal Vein
RFLP		Restriction Fragment Length Polymorphism
RHV		Right Hepatic Vein
S		Significant
SD		Standard Deviation
TIPS		Transjugular Intrahepatic Portosystemic Shunt
TLC		Total Leucocytic Count
TYK2		Tyrosine Kinase 2

List of Tables

Table No.	Title	Page
Table (1):	Approximate prevalence of major risk factors in primary BCS patients	8
Table (2):	Proportion of patients with FVL mutation in unselected patients with BCS in non-European countries or Turkey, ranked by increasing order	10
Table (3):	Specific features of hepatic vein obstruction	18
Table (4):	Workup in newly diagnosed Budd-Chiari patient.....	22
Table (5):	WHO criteria for Polycythemia vera 2016	23
Table (6):	WHO criteria for essential thrombocythemia (2016)	23
Table (7):	WHO overt Primary myelofibrosis criteria (2016)	24
Table (8):	Prognostic scores in Budd–Chiari syndrome	31
Table (9):	JAK2 mutations in myeloproliferative neoplasms.....	40
Table (10):	The prevalence of JAK2-V617F mutation in unselected patients with BCS in non-European countries or Turkey, ranked by increasing order	41

List of Tables (Continued)

Table No.	Title	Page
Table (11):	Various JAK2V617F mutation detection methods	44
Table (12):	Temperature profile	5
Table (13):	Interpretation of genotyping results using normalized ratios	56
Table (14):	Description of demographic and clinical data	58
Table (15):	Description of laboratory and radiological data	59
Table (16):	Description of etiological factors of Budd Chiari Syndrome	61
Table (17):	Comparison between idiopathic and secondary cases as regards demographic and laboratory data	62
Table (18):	Comparison between negative and positive JAK2 V617F mutation cases as regards demographic, clinical and laboratory data	63
Table (19):	Comparison between negative and positive JAK2 V617F mutation cases as regards etiology of BCS	64
Table (20):	Comparison between negative and positive JAK2 V617F mutation cases as regards associated secondary pro-thrombotic factors	65
Table (21):	Comparison between occult and overt MPNs	67
Table (22):	Master sheet of all studied patients	68

List of Figures

Figure No.	Title	Page
Fig. (1):	Algorithm for the diagnosis of MPNs associated BCS	13
Fig. (2):	Proposed assessment scheme for patients with BCS HVOTO: hepatic venous outflow tract obstruction, IVC: inferior vena cava	17
Fig. (3):	Right hepatic venogram showing extensive intrahepatic collateral formation likened to a “spider web” appearance	20
Fig. (4):	Proposed algorithm for management of Budd–Chiari syndrome. HVOTO: hepatic venous outflow tract obstruction	29
Fig. (5):	JAK2 gene is located on the short (p) arm of chromosome 9 at position 24....	33
Fig. (6):	Domain organization in JAK2, Positive- and negative-regulatory phosphorylation sites (colored green and red, respectively). Select activating mutations in JH2 and JH1 are shown below the domains.....	34
Fig. (7):	(Left) crystal structure of the JAK1 FERM and SH2L domains The FERM domain. (Right) crystal structure of JH2 and JH1 domains	36
Fig. (8):	Steps of DNA extraction.....	49

List of Figures (Continued)

Figure No.	Title	Page
Fig. (9):	TaqMan probe multiplex assay. The ipsogen JAK2 MutaScreen Kit uses this technology for allelic discrimination.....	51
Fig. (10):	Positive heterozygous mutation, dotted curve represent VIC dye (wild gene) while continuous curve represent FAM dye (mutant gene)	52
Fig. (11):	Slan 96P real time PCR System	54

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof/ Iman Mohamed Amin Omar**, Professor of Clinical Pathology - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made the completion of this work possible.*

*I am also delighted to express my deepest gratitude and thanks to **Dr./ Botheina Ahmed Thabet Farweez**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kind care and continuous supervision.*

*I'd like to thank **Dr./ Mona Fathey Abd Elfatta**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her valuable instructions and constant help.*

*I'd like to thank **Dr./ Noha Bassiouny Hassan Mostafa**, Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her great assistance and continuous guidance throughout this work.*

*Much gratitude is expressed to **Dr./ Ahmed Samir Abdel-Moaty Abdel-Halym**, Lecturer of tropical medicine, Faculty of Medicine, Ain shams University, for his great effort and continuous supervision in providing us with our targeted patients and their data.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Esraa Mansour Shehata

Introduction



Aim of the Study



Review of Literature



BUDD CHIARI SYNDROME



JANUS KINASES



Subjects and Methods

